The drug is a genetically modified erythropoietin hormone, which is responsible for producing red blood cells in the same process as the natural process in the body.
The drug is designed to treat anemia caused by chronic kidney failure in dialysis patients and non-dialysis-dependent patients (in adults and children over one month), to treat anemia in Zidobudine-treated AIDS patients, to anemia created as a treatment for cancer patients, and to treat patients in need of surgery.
Other Uses Unregistered: Treatment of premature anemia, among patients with chronic inflammatory disease (such as rheumatoid arthritis), cancer patients who are not being treated as therapeutic, and among hepatitis C patients treated with ribavirin.
Use of alpha apoetin may, inter alia, cause blood clots, polycythemia, and even the development of antibodies against erythropoietin. During the period of treatment with epoetin alfa, the following tests are recommended: Blood counts include platelet counts, blood pressure, and hemoglobin levels.